SARMs
Ostarine (MK-2866)
Ostarine (MK-2866) is a mild SARM commonly used in recomposition research. Below, we compare vendors currently stocking research-grade Ostarine — not just a single sales page.
Ostarine (MK-2866) is a mild SARM commonly used in recomposition research. Below, we compare vendors currently stocking research-grade Ostarine — not just a single sales page.
Prices and testing claims are pulled from each vendor's product listing. Always confirm current price and COA (Certificate of Analysis) on the vendor's site before buying.
| Vendor | Price | Purity Testing | Code | |
|---|---|---|---|---|
 MuscleChemBest Value |
£44.99 | In-house testing | Buy Here → | |
 UK Sarms |
£54.97 | Third-party COA | Auto-applied | Buy Here → |
 Chemyo |
$69.99 (25mg/ml solution) | Third-party COA | Buy Here → |
Ostarine (MK-2866, Enobosarm) is a nonsteroidal selective androgen receptor modulator (SARM) originally developed by GTx Inc., one of the earliest and most-studied SARMs, with a more developed human clinical trial record than most other compounds in the class.
Research-grade Ostarine is typically supplied as capsules or a liquid solution, commonly at 10mg or 25mg per capsule, intended for laboratory research use only.
Ostarine binds the androgen receptor and is studied for producing tissue-selective anabolic effects in muscle and bone with reduced activity in other androgen-sensitive tissue compared to testosterone, the shared mechanistic premise of the SARM drug class.
Ostarine has been studied in Phase 2 human clinical trials for cancer cachexia and age-related muscle loss, where trial data showed increases in lean body mass, giving it one of the stronger human-trial safety and efficacy records among SARMs.
Because androgen receptor activation also affects bone tissue, Ostarine has additionally been studied in models and trials examining bone mineral density, an area of interest for its potential use in osteoporosis-adjacent research.
Ostarine's Phase 2 trials reported it was generally well tolerated at studied doses over the trial periods, though it has not completed the Phase 3 program required for FDA approval, so no approved product exists. It is banned by the World Anti-Doping Agency, and case reports outside formal trials have raised concerns about liver enzyme changes and suppression of natural testosterone production.
Doses used in published Phase 2 clinical trials are documented in that trial literature and are specific to those regulated study protocols; no FDA-approved commercial dosage exists for Ostarine research material.
Compound X does not sell Ostarine (MK-2866) directly. We provide independent research, comparisons and vendor links — see the vendor comparison table above for current US, UK, Canada and Australia options.
Ostarine/Enobosarm clinical trial data is indexed on PubMed under "Ostarine MK-2866 Enobosarm clinical trial" and "GTx SARM cachexia."
New guides, vendor comparisons and compound breakdowns every week.